Literature DB >> 9111616

How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium.

J Altwein1, P Ekman, M Barry, C Biermann, P Carlsson, S Fosså, G Kiebert, T Küchler, D McLeod, A Porter, G Steineck.   

Abstract

OBJECTIVES: To identify complications of various forms of treatments for prostate cancer and their influence on patients' quality of life with the ultimate goal of suggesting a Quality of Life Questionnaire specific for prostate cancer for further validation.
METHODS: The literature was screened for reports on the more common complications following various forms of therapy for prostate cancer. Frequencies were summarized. The scarce literature reporting on quality of life in prostate cancer was reviewed and conflicting data were discussed and reassessed. Suggested questionnaires used in other studies were critically scrutinized and the various questions recorded.
RESULTS: Following radical surgery, impotence and incontinence were the most common complications reducing patients' quality of life. The literature was not uniform with regard to whether loss of sexual function was regarded as a worse complication than loss of urinary control. Following radiotherapy, intestinal problems and sexual dysfunction were the dominating side effects. Quality of life was best preserved in surveillance-only series. Following endocrine therapy, not only impotence and hot flushes were focused upon, but also mental dysfunction and intestinal dysfunction from nonsteroidal antiandrogens, additionally, the importance of effective palliation was highlighted. A Quality of Life Questionnaire should contain general domains relevant to cancer patients, cancer-specific questions, and prostate-cancer-specific questions. The latter group includes: worry for prostate cancer and its prognosis, bone/pelvic pain, lower urinary tract symptoms, urinary incontinence, urinary diversion, bowel function, sexual function, endocrine effects, and satisfaction with medical care for prostate cancer.
CONCLUSIONS: A modern trial of prostate cancer treatment should be regarded as insufficient without including a validated Quality of Life Questionnaire.

Entities:  

Mesh:

Year:  1997        PMID: 9111616     DOI: 10.1016/s0090-4295(99)80325-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Relationship with God and the quality of life of prostate cancer survivors.

Authors:  Terry Lynn Gall
Journal:  Qual Life Res       Date:  2004-10       Impact factor: 4.147

Review 2.  Bicalutamide in advanced prostate cancer. A review.

Authors:  K L Goa; C M Spencer
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

3.  The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer.

Authors:  D F Penson
Journal:  Rev Urol       Date:  2001

Review 4.  Prostate cancer and health-related quality of life: a review of the literature.

Authors:  David T Eton; Stephen J Lepore
Journal:  Psychooncology       Date:  2002 Jul-Aug       Impact factor: 3.894

5.  Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey.

Authors:  J H Kim; Y-S Ha; S J Jeong; S Kim; W-J Kim; T L Jang; I Y Kim
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-08-06       Impact factor: 5.554

6.  Small integrin-binding proteins as serum markers for prostate cancer detection.

Authors:  Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

7.  The Development of iManage-PC, an Online Symptom Monitoring and Self-management Tool for Men With Clinically Localized Prostate Cancer.

Authors:  Karly M Murphy; Christina Sauer; Dershung Yang; Niina Hass; Kristian Novakovic; Brian Helfand; Robert Nadler; Benjamin D Schalet; David Victorson
Journal:  Cancer Nurs       Date:  2022 Jan-Feb 01       Impact factor: 2.592

8.  Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.

Authors:  Carlos Anselmo Lima; Brenda Evelin Barreto da Silva; Evânia Curvelo Hora; Marcela Sampaio Lima; Erika de Abreu Costa Brito; Marceli de Oliveira Santos; Angela Maria da Silva; Marco Antonio Prado Nunes; Hugo Leite de Farias Brito; Marcia Maria Macedo Lima
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

9.  Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms.

Authors:  Charles C Anunobi; Komal Koli; Geetu Saxena; Adekunbiola A Banjo; Kalu U E Ogbureke
Journal:  Oncotarget       Date:  2016-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.